Regen BioPharma Inc (RGBP)

[TAKURI]

KCL Therapeutics, Inc., a wholly-owned subsidiary of Regen BioPharma, Inc. has been granted patent protection by the U.S. Patent and Trademark Office for the application titled “Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans.” $RGBP $RGBPP

12:24 AM · 18 mai 2022.

KCL Therapeutics, Inc., a wholly-owned subsidiary of Regen BioPharma, Inc. has been granted patent protection by the U.S. Patent and Trademark Office for the application titled “Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans.” $RGBP $RGBPP

— Regen BioPharma Inc. (@TheRegenBio) May 17, 2022